No abstract available.
Hemorrhage ; Metoclopramide

No abstract available.
Blood Pressure* ; Metoclopramide* ; Rabbits*

For postmenopausal women who fear hormone therapy, women 60 years of age with continuous, severe hot flushing or women with a history of breast cancer, we should consider selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs) as therapeutic agents. Base on the results from a meta-analysis and clinical trials regarding hot flushing, paroxetine and the conetrolled-release formultation of paroxetine have been shown to effectively reduce hot flushing by 30~40% and 60~70%, respectively, and 13~41% more reductions as compared to placebo. Venlafaxine reduced hot flushes by 30~60% (133% reductions compared to placebo), and desvenlafaxine reduced hot flushes by 30~70%. Fluoxetine and citalopram were shown to be less effective than paroxetine and venlafaxine, by 20% (113% reductions compared to placebo) and 40~50%, respectively. Sertraline reduced hot flushes 3~18% compared to the placebo group, but was considered ineffective. Citalopram (20 mg), paroxetine (10 mg), venlafaxine (37.5~150 mg), and desvenlafaxine (100~200 mg) not only reduced vasomotor symptoms, but demonstrated additional beneficial outcomes with respect to sleep disturbances, mood, the vigor index, and improved quality of life. Citalopram (20 mg), fluoxetine (20 mg), paroxetine (10 mg), venlafaxine (75~150 mg), and desvenlafaxine (150 mg) are recommended at the corresponding doses after weighing the risks and benefits of these medications. SSRIs and SNRIs were shown to interrupt the conversion of tamoxifen into the active metabolite, endoxifen, and thus SSRIs and SNRIs must not be used in breast cancer patients who are taking tamoxifen. Paroxetine suppressed vasomotor symptoms most potently, followed by fluoxetine, sertraline, citalopram, and venlafaxine.
Breast Neoplasms ; Citalopram ; Cyclohexanols ; Female ; Fluoxetine ; Flushing ; Humans ; Menopause ; Norepinephrine ; Paroxetine ; Quality of Life ; Risk Assessment ; Serotonin ; Serotonin Uptake Inhibitors ; Sertraline ; Tamoxifen ; Desvenlafaxine Succinate ; Venlafaxine Hydrochloride

No abstract available.
Antiemetics* ; Cisplatin* ; Dexamethasone* ; Humans ; Lorazepam* ; Metoclopramide* ; Ondansetron*

No abstract available.
Disorders of Excessive Somnolence ; Humans ; Metoclopramide ; Parkinsonian Disorders

Venlafaxine is among the most widely prescribed antidepressants. It is extensively metabolized to O-desmethylvenlafaxine via cytochrome P450 (CYP) 2D6. We report a case of acute toxic hepatitis resulting from venlafaxine in a 54-year-old woman with pain disorder. During venlafaxine treatment, laboratory tests revealed elevated liver enzymes with a maximum of 169 IU/L for aspartate transaminase (AST) and 166 IU/L for alanine transaminase (ALT). AST and ALT levels returned to normal after 6 days of discontinuation of venlafaxine. The patient was finally diagnosed with acute toxic hepatitis through liver biopsy. This case indicates the importance that clinicians should be aware of the hepatotoxicity of venlafaxine in practice.
Alanine Transaminase ; Antidepressive Agents ; Aspartate Aminotransferases ; Biopsy ; Cyclohexanols ; Cytochrome P-450 Enzyme System ; Drug Toxicity ; Drug-Induced Liver Injury ; Female ; Humans ; Liver ; Middle Aged ; Somatoform Disorders ; Desvenlafaxine Succinate ; Venlafaxine Hydrochloride

No abstract available.
Drug Therapy, Combination* ; Metoclopramide* ; Ondansetron* ; Prospective Studies* ; Vomiting*

Methods: In a randomized, double-blinded, placebo-controlled trial, 144 ASA I-II patients, scheduled for elective surgery under general anesthesia were randomly assigned to 1 of 4 groups. Group I received 2 ml of plain NSS, group II received lidocaine 40 mg, group III received thiopental 0.5mg/kg and group IV received metoclopramide 10 mg. All pretreatment drugs were made into 2 ml solutions and were given IV with manual venous occlusion of 1 minute. Propofol was administered after release of venous occlusion. pain was then assessed using a four-point scale and face pain scale during propofol injection. Results: 36 patients (100%) complained of pain in the control group compared with 20 (56%), 22 (61%) and 23 (64%) in the lidocaine, thiopental and metoclopramide groups, respectively (p<0.05). there was no significant difference among the 3 test solution with regards to severity of pain. Nor were there any noted complications 24 hours postoperatively on the injection site. Conclusion: Thiopental and metoclopramide are equally effective as lidocaine in reducing pain during propofol injection when used with manual venous occlusion.
Human ; LIDOCAINE ; THIOPENTAL ; METOCLOPRAMIDE ; PROPOFOL ; PAIN MANAGEMENT ; ANESTHESIA

PURPOSE: There have been few studies concerned with the hiccup patients who visit the emergency department. The purpose of this study is to investigate the epidemiology and clinical characteristics of hiccup patients. METHODS: We retrospectively reviewed 60 hiccup patients who visited the emergency departments of Chungbuk National University Hospitals, Chungnam National University Hospital and Chonnam National University Hospital in Korea from January 2005 to December 2007. We categorized the patients into 2 groups of the discharged and the admitted and also into groups of patients who had different types of treatments. We compared clinical outcomes and characteristics of the groups. RESULTS: A total of 60 cases of hiccup patients visited the emergency department from January 2005 to December 2007. There was a significant difference in the recovery rate from hiccups between the discharged group and the admission group (72.4% & 100.0%, p=0.04). The 3 major drugs used for treatment were metoclopramide, chlorpromazine, and benzodiazepine. The patients showed a broad spectrum for the final diagnosis, from the benign hiccups to ischemic stroke in the pons area. CONCLUSION: In this study, the hiccup patients who visited the ED showed simple temporal signs to various severe diseases such as the ischemic stroke in the pons. These findings can be useful reference for the decision making at admission or discharge and for predicting the prognosis of the hiccup patients who visit the emergency department.
Benzodiazepines ; Chlorpromazine ; Decision Making ; Emergencies ; Hiccup ; Hospitals, University ; Humans ; Korea ; Metoclopramide ; Pons ; Prognosis ; Retrospective Studies ; Stroke

BACKGROUND: Rocuronium has a high incidence of inducing pain by intravenous injection, and different methods have been used to minimize the incidence and severity of this pain. In this study, we have compared the effects of lidocaine and metoclopramide pretreatments on rocuronium injection pain. METHODS: Ninety healthy patients scheduled for general anesthesia were randomly divided into three groups; a saline group (n = 30), a lidocaine group (n = 30), and a metoclopramide group (n = 30). Each patient received 2 ml of pretreatment solution (normal saline, 2% lidocaine, or 0.5% metoclopramide) via an 18 G angiocatheter inserted in the antecubital fossa after applying an arm tourniquet inflated to 50 mmHg. The tourniquet was released 1 minute later, and this was followed by an intravenous injection of 0.6 mg/kg of rocuronium. General anesthesia then induced with thiopental sodium (5 mg/kg). The assessment of pain was made at the induction of anesthesia and in the recovery room, and the severity of pain was classified as none, mild, moderate, or severe by an observer. RESULTS: The severity and incidence of pain diminished significantly in the lidocaine and metoclopramide groups compared with the saline group at the induction of anesthesia (P < 0.05), but no significant difference was observed between the lidocaine and metoclopramide groups. Similar results were obtained in the recovery room; one patient in each of the saline and metoclopramide groups had no recall regarding injection pain. CONCLUSIONS: Intravenous metoclopramide pretreatment is as effective as intravenous lidocaine pretreatment for alleviating rocuronium injection pain.
Anesthesia ; Anesthesia, General ; Arm ; Humans ; Incidence ; Injections, Intravenous ; Lidocaine* ; Metoclopramide* ; Recovery Room ; Thiopental ; Tourniquets